Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists. Ron JG Peters, MD On behalf of the RESPONSE Investigators Academic Medical.

Slides:



Advertisements
Similar presentations
Sutter Medical Foundation Diabetes Management Program Kimberly Buss, MD, MPH Medical Director of Diabetes Education, SMF Medical Advisor of Diabetes.
Advertisements

Change in Abdominal Obesity & Risk of Coronary Calcification Siamak Sabour, MD, MSc, DSc, PhD, Postdoc Clinical Epidemiologist Persian International Epidemiology.
EUROACTION: Changes in diet and physical activity over one year in a family based preventive cardiology programme in hospital and general practice Jennifer.
THE ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY (ACCORD)
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
K Fox, W Remme, C Daly, M Bertrand, R Ferrari, M Simoons On behalf of the EUROPA investigators. The diabetic sub study of.
The INSIGHT study - Reliable blood pressure control and additional benefits for hypertensive patients Anthony M Heagerty Department of Medicine Manchester.
Henry C. Ginsberg, MD College of Physicians & Surgeons, Columbia University, New York For The ACCORD Study Group.
Blood Pressure Reduction Among Acute Stroke Patients A Randomized Controlled Clinical Trial Jiang He, Yonghong Zhang, Tan Xu, Weijun Tong, Shaoyan Zhang,
Diabetes Mellitus Type 2
Facts and Fiction about Type 2 Diabetes Michael L. Parchman, MD Department of Family & Community Medicine September 2004.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
LIFESTYLE MODIFICATIONS FOR PREVENTING HEART DISEASE [e.g. HEART ATTACKS] [ primary prevention of coronary artery disease ] DR S. SAHAI MD [Med.], DM [Card]
Diabetes Trials Unit University of Oxford WebSite: Lipids in Diabetes Study.
Minimally Invasive Surgery Symposium Modest Weight Loss in T2 DM: Lessons from the Look AHEAD Trial Donna H. Ryan, MD Pennington Biomedical Research Center.
HYPERLIPIDAEMIA. 4S 4444 patients –Hx angina or MI –Cholesterol Simvastatin 20mg (10-40) vs. placebo FU 5 years  total cholesterol 25%;  LDL.
December Cardiac Rehabilitation Are you or someone you know missing the benefits of Cardiac Rehabilitation?
RISK FACTOR FOR CORONARY ARTERY DISEASE
1FHI 360 Nigeria. 2USAID Nigeria
Heart Health Project University of Pennsylvania School of Medicine American Heart Association Pennsylvania State University Funded by the Robert Wood Johnson.
AN ASSESSMENT OF THE PRIMARY PREVENTION CONTROL PROGRAM OF PHC PREVENTIVE CARDIOLOGY CLINIC AMONG PATIENTS AT RISK FOR CVD: A Retrospective Cohort Study.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar Dr.PH. Batch 5 1.
Modern Management of Cholesterol in the High-Risk Patient.
MEDication Focused Outpatient Care for Underutilization of Secondary Prevention (MEDFOCUS) Matt Arnold, PharmD Site Investigator Genesis Quad Cities Family.
ALPHA OMEGA: Effect of low doses of n-3 fatty acids on cardiovascular diseases in post-MI patients Daan Kromhout, MPH PhD for the Alpha Omega Trial Group.
Background  Obesity is an extremely common problem ~ 1/3 of adult Americans are obese  Patients commonly ask physicians for advice on weight loss, yet.
Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial On behalf of the TRILOGY ACS.
EFFECTIVENESS OF A MEDICAL EDUCATION INTERVENTION TO TREAT HYPERTENSION IN PRIMARY CARE Authors Institutions Authors: Silvia Martínez-Valverde MSc 1, Hortensia.
Laura Mucci, Pharm.D. Candidate Mercer University 2012 Preceptor: Dr. Rahimi February 2012.
Incremental Decrease in Clinical Endpoints Through Aggressive Lipid Lowering (IDEAL) Trial IDEAL Trial Presented at The American Heart Association Scientific.
Studying mortality trends: The IMPACT CHD Policy Model
Copyleft Clinical Trial Results. You Must Redistribute Slides HYVET Trial The Hypertension in the Very Elderly Trial (HYVET)
ABSTRACT Diabetes is a public health issue of growing magnitude. It currently ranks among the top ten leading causes of death in the United States. To.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
Cardiovascular Disease Healthy Kansans 2010 Steering Committee Meeting April 22, 2005.
Effect of Hypertension and Dyslipidemia on glycemic control among Type 2 Diabetes patients in Thailand Dr. Mya Thandar DrPH Batch 5 1.
The Renin-Angiotensin- Aldosterone System: Linking New Data and Mechanisms for Cardiovascular Risk Reduction VBWG.
Pharmacist-Physician Collaborative Medication Therapy Management Services (MTMS) PI: Jan Hirsch, RPh, PhD Carol M. Mangione, MD, MSPH Barbara A. Levey.
Prevention of Dementia by Intensive Vascular Care - preDIVA-trial
BRIAN CLAYTON INTERNAL MEDICINE ADVISOR: ANNA MAE SMITH PRECEPTOR: DR. RAJESH PATEL Evidence Based Medicine Spring 2009.
Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Clinical and Economic Benefits Associated With the Achievement of Both HbA1c and LDL Cholesterol Goals in Veterans With Type 2 Diabetes Featured Article:
Long-term Cardiovascular Effects of 4.9 Years of Intensive Blood Pressure Control in Type 2 Diabetes Mellitus: The Action to Control Cardiovascular Risk.
Laboratory Testing For Cardiovascular Risk
Ross T. Tsuyuki, BSc(Pharm), PharmD, MSc, FCSHP, FACC Yazid NJ Al Hamarneh, BPharm, PhD Charlotte Jones, MD, PhD, FRCP(C) Brenda Hemmelgarn, MD, PhD, FRCP(C)
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults Scott W. Rypkema, M.D.
Vitamin D: A New Frontier in Diabetes Management Contact Information: Background Acknowledgement Methods.
The MICRO-HOPE. Microalbuminuria, Cardiovascular and Renal Outcomes in the Heart Outcomes Prevention Evaluation Reference Heart Outcomes Prevention Evaluation.
Clara K. Chow, MBBS, PhD; Julie Redfern, PhD; Graham S. Hillis, MBChB, PhD; Jay Thakkar, MBBS; K arla Santo, MBBS; Maree L. Hackett, PhD; Stephen Jan,
Journal Club Julie Shah, MD Milton S Hershey Medical Center Penn State University.
The JUPITER Trial Reference Ridker PM. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008;359:2195–2207.
Date of download: 6/21/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Effectiveness of Pharmacist Interventions on.
Date of download: 6/22/2016 Copyright © The American College of Cardiology. All rights reserved. From: The Year in Hypertension J Am Coll Cardiol. 2006;48(8):
Statins The AURORA Trial Reference Fellstrom BC. Rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360. A.
The OPTImal CArdiac REhabilitation (OPTICARE) trial:
Summary of “A randomized trial of standard versus intensive blood-pressure control” The SPRINT Research Group, NEJM, DOI: /NEJMoa Downloaded.
Dr John Cox Diabetes in Primary Care Conference Cork
Effects of a comprehensive community-based lifestyle intervention in patients with coronary artery disease: the trial.
Effects of a comprehensive community-based lifestyle intervention in patients with coronary artery disease: the trial.
The SPRINT Research Group
Copyright © 2015 American Medical Association. All rights reserved.
Impact and costing of cardiovascular disease treatmentin Kwara State Health Insurance (KSHI) program. University of Ilorin Teaching Hospital (UITH) Amsterdam.
The Anglo Scandinavian Cardiac Outcomes Trial
The Hypertension in the Very Elderly Trial (HYVET)
Insights from the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
LDL Cholesterol.
New Lipid-Lowering Guidelines
The Heart Truth Delaware Background
The following slides highlight a report on a presentation at the American College of Cardiology 2004, Scientific Sessions, in New Orleans, Louisiana on.
Many post-MI patients are not receiving optimal therapy
Presentation transcript:

Randomised Evaluation of Secondary Prevention by Outpatient Nurse SpEcialists. Ron JG Peters, MD On behalf of the RESPONSE Investigators Academic Medical Center - University of Amsterdam The Netherlands

Support Unrestricted grant from AstraZeneca, the Netherlands. No conflicts of interest

Background Secondary prevention may effectively prevent recurrent cardiovascular events. Guidelines have been issued by ESC, AHA/ACC A gap exists between these guidelines and clinical practice New, practical initiatives are needed to reduce this gap

Study design Study goal: To quantify the impact of a nurse coordinated prevention program on risk factor levels in patients with a recent coronary event

Study design Multicenter (n=11) randomised clinical trial in The Netherlands Patients: years (n=754) Discharged after ACS (unstable angina/AMI)

Study flowchart Primary outcome blinded

Primary outcome SCORE risk estimate at 12 months 10-year cardiovascular mortality – Gender & Age – Smoking status – Total cholesterol – Systolic blood pressure

Targets Nurse Intervention

Baseline characteristics

risk factors: proportion on target

Medication

5.4% Primary outcome calculated 10 year mortality (SCORE)

p= % 4.5% RR reduction 16.9% Complete attendance 93.3%

Framingham risk estimation (Secondary Outcome)

risk factors: proportion on target

Diabetes Mellitus Identified as diabetic and referred, but no diagnosis:

Classification of achievement of risk factor targets

Conclusions (1) The RESPONSE nurse coordinated prevention program resulted in lowering of cardiovascular risk in patients with a recent acute coronary event. This was achieved on top of high level usual care. Risk reduction was sustained at follow-up.

Conclusions (2) The program was effective in achieving targets for systolic blood pressure, LDL cholesterol, and healthy lifestyles. The program did not impact on weight and smoking status. Insulin resistance was highly prevalent but received insufficient attention.

Conclusions (3) The program, with up to 4 outpatient clinic visits, was well attended and feasible. The nurse coordinated prevention program can readily be implemented into daily practice.

Acknowledgements: our nurses Janine Doornenbal Annemarie von Drimmelen Harold Helmes Irma Kremer Franciska Kuijper Rob Lardinois Naomi Moerman Annie Obbema Aafje Reijenga Leon Schotman Lennie Setten van der Meer Ira van Sleeuwen Ann Klein Twennaar Eelkje Wolf Doetie van der Woude

RESPONSE study group